Sugi Predict

Sugi Predict / Compounds / SCHEMBL1107420

SCHEMBL1107420

SCHEMBL1107420

CCOC(=O)Cc1csc(C)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.68
▸ KMT2A Q03164 4/20 0.68
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ GAA P10253 1/20 0.59
▸ ALDH1A1 P00352 3/20 0.58
▸ LMNA P02545 3/20 0.57
▸ MAPK1 P28482 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ HTT P42858 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ POLB P06746 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ ESR2 Q92731 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5442409 0.87 MEN1 (0.54) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL11012092 0.85 MEN1 (0.66) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1525238 0.85 MEN1 (0.66) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL9709994 0.84 SMN1; SMN2 (0.54) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL12548631 0.84 KMT2A (0.64) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1810023 0.83 MEN1 (0.64) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL10755054 0.83 KMT2A (0.64) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL8445 0.83 MEN1 (0.64) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL4519283 0.83 MEN1 (0.64) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL19525943 0.83 SMN1; SMN2 (0.53) MEN1KMT2ASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. 2025-06-12 — — US disclosed
EP-4469457-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS The Broad Institute Inc. (US) 2024-12-04 — — EP disclosed
US-11724987-B2 Compositions and methods of treating retinal disease ALDEYRA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
WO-2023147015-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. (US) 2023-08-03 — — WO disclosed
EP-3668512-B1 PYRUVATE KINASE MODULATORS AND USE THEREOF AGIOS PHARMACEUTICALS INC (US) 2023-02-15 — — EP disclosed
US-20220363709-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF ANTENGENE THERAPEUTICS LIMITED (CN) 2022-11-17 — — US disclosed
EP-3986894-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF Calithera Biosciences, Inc. (US) 2022-04-27 — — EP disclosed
CN-114008048-A Exonucleotidase inhibitors and methods of use thereof 卡利泰拉生物科技公司 2022-02-01 — — CN disclosed
WO-2020257429-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF CALITHERA BIOSCIENCES, INC. (US) 2020-12-24 — — WO disclosed
EP-3181554-B1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2020-10-28 — — EP disclosed
EP-1644320-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-04-12 — — EP disclosed
CN-1633434-A Imidazo [1, 2-a ] pyridine derivatives DAIICHI SEIYAKU CO (JP) 2005-06-29 — — CN disclosed
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 — — US disclosed
WO-2005009941-A1 INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-02-03 — — WO disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 — — EP disclosed
WO-2003076403-A1 1,2-DISUBSTITUDED-6-OXO-3-PHENYL-PIPERIDINE-3-CARBOXAMIDES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2003-09-18 — — WO disclosed
US-20030171588-A1 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof LION BIOSCIENCE AG (DE) 2003-09-11 — — US disclosed
US-4683227-A CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1987-07-28 — — US disclosed
EP-0211526-A2 Cephalosporins, their preparation and formulations ELI LILLY AND COMPANY (US) 1987-02-25 — — EP disclosed
US-4033978-A Thiacycl[2.2.2]azine carboxylic acids SYNTEX (U.S.A.) INC. (US) 1977-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220363709-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF NT5E, ENTPD5, NT5C2 MEN1 1731/4885KMT2A 3055/4885SMN1; SMN2 3679/4885
US-20030171588-A1 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof BRD4, BICRA, HDAC6 MEN1 4019/4885KMT2A 202/4885SMN1; SMN2 1499/4885
US-11724987-B2 Compositions and methods of treating retinal disease ALDH1A2, PLA2G2E, CLN6 MEN1 3299/4885KMT2A 3623/4885SMN1; SMN2 507/4885
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 MEN1 2268/4885KMT2A 4210/4885SMN1; SMN2 2642/4885
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS CSNK1A1, CSNK2A1, CSNK1A1L MEN1 1809/4885KMT2A 899/4885SMN1; SMN2 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.